Takeda Pharmaceutical Co (TSE:4502) LT-Debt-to-Total-Asset: 0.28 (As of Mar. 2026)

What is Takeda Pharmaceutical Co LT-Debt-to-Total-Asset?

Takeda Pharmaceutical Co TSE:4502 +0.06% 65 LT-Debt-to-Total-Asset is 0.28 as of Mar. 2026. GuruFocus rates TSE:4502 with a GF Score™ of 65/100 and a GF Value™ of 円4,535.84 (Modestly Overvalued). The stock has 10 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Takeda Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.28.

Takeda Pharmaceutical Co's long-term debt to total assets ratio increased from Mar. 2025 (0.28) to Mar. 2026 (0.28). It may suggest that Takeda Pharmaceutical Co is progressively becoming more dependent on debt to grow their business.

Takeda Pharmaceutical Co (TSE:4502) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Takeda Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Takeda Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Takeda Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Takeda Pharmaceutical Co Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.31

0.29

0.30

0.28

Takeda Pharmaceutical Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.28	0.30	0.30	0.28	0.28

65GF Score

Takeda Pharmaceutical Co Ltd TSE:4502

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Takeda Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Takeda Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )	/	Total Assets (A: Mar. 2026 )
	=	4369681	/	15511506
	=	0.28

Takeda Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	4369681	/	15511506
	=	0.28

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.28 mean?

Takeda Pharmaceutical Co (TSE:4502) has a LT-Debt-to-Total-Asset of 0.28 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Takeda Pharmaceutical Co and its competitors.

Is Takeda Pharmaceutical Co's LT-Debt-to-Total-Asset too high?

Takeda Pharmaceutical Co's current LT-Debt-to-Total-Asset is 0.28. Overall, Takeda Pharmaceutical Co has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Takeda Pharmaceutical Co's LT-Debt-to-Total-Asset compare to ZTS and UTHR?

Takeda Pharmaceutical Co's LT-Debt-to-Total-Asset of 0.28 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current LT-Debt-to-Total-Asset is 0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Takeda Pharmaceutical Co stock overvalued right now?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TSE:4502) is currently considered Modestly Overvalued. The stock's GF Value™ is 円4,535.84, compared to a current price of 円5,451.00 — trading 20.2% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.28. Takeda Pharmaceutical Co's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TSE:4502), the current LT-Debt-to-Total-Asset is 0.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takeda Pharmaceutical Co (TSE:4502) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of 円5,451.00 is trading 20.2% above its estimated GF Value™ of 円4,535.84. GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for TSE:4502:

LT-Debt-to-Total-Asset: 0.28
GF Value™: 円4,535.84 vs. price of 円5,451.00 (20.2% above fair value)
GF Score™: 65/100 with 10 warning signs

No single metric tells the full story. See the TSE:4502 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Takeda Pharmaceutical Co Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TSE:4507 TSE:4151 TSE:4523 TSE:4506 TSE:4540 TSE:4516 TSE:4887 TSE:4553 TSE:4547 TSE:4521 XTER:MRK XSWX:GALD SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR HKSE:03692

Other Exchanges TAK:USA TKPHF:USA 0A87:UK TKD:Germany

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668

Website https://www.takeda.com

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.

65GF Score

Get the complete analysis for TSE:4502

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円5,451.00

Price

円4,535.84

GF Value

View TSE:4502 Analysis

See LT-Debt-to-Total-Asset data for all stocks →